LLY 2X Long ETF

$Eli Lilly(LLY.US)

Merck and moderna are good examples of what it means to get in and be patient. Lily is pumping so much money into research and with AI we might find a cure for diabetes. Get in and be patient. Trials take time for approvals. Diversify from tech!

$Eli Lilly(LLY.US)

Context: Eli Lilly has had a strong run, gaining about 30% since March as investors remain optimistic about its diabetes and obesity drug business. The stock has also recently reached new highs.

My trade: I closed my position last night after the strong rally. Rather than chase the stock higher, I’m happy to lock in the gains.

Takeaway: I know Lilly remains a strong growth story but expectations are also high. Also, pharma stocks face risks from drug pricing pressure, competition, regulation, and the uncertainty of developing new treatments.

$Eli Lilly(LLY.US)

Many investors often wonder if there are good alternatives to the tech bubble. Eli Lily is such a brand. Very good moat and good product. It is likely to invent and patent more than its competitor due to good cashflow. Stay vested early!

#Trade Showcase: Trade, Show & Earn Rewards!

Dow +263 points to a record 54,349 while Nasdaq gave up 0.83% to 26,363 and S&P slipped 0.17%. same session. healthcare carried the Dow with Lilly +4.9% and Amgen +4.6% while the AI complex paid for the earnings reactions. this is rotation, not risk off, and the two get confused constantly.

For the first time, DBS’ total income is above SGD6 billion. SpaceX reports as a public company. AppLovin revenue jumps. Eli Lilly, Shopify and Disney gains range from 3% to 17%.

Good news for CapitaLand Ascendas REIT distributes income up to 8.6% DPU of 7.482 cents.

CapitaLand China Trust → DPU of 2.45 cents.

There are more news about Hong Kong / China stocks - Hang Seng China Enterprises, MiniMax, Luxshare Precision, and Sanhuan Group.

$Eli Lilly(LLY.US) (+5% today) now has two of the top 10 selling drugs in the world: #1 Mounjaro for type 2 diabetes (est 2026 Revs $36B), and #6 Zepbound for weight loss (est 2026 Revs $18B), plus 6 other drugs with more than $1B in expected 2026 revenues. When a pharma rep has a product platform that deep, it gives the sales rep a huge advantage to sell in both new delivery forms for existing treatments (e.g. LLY’s GLP-1 weight loss pill Foundayo) and for new treatments (LLY’s Kisunla for Alzheimer’s, which should generate $600M sales in FY’2026). At 35x 2026 Adj EPS, LLY is certainly not cheap vs +12-15% long-term rev growth and +18-20% EPS growth but it’s a great play on weight loss, type 2 diabetes, and aging.

$Eli Lilly(LLY.US) +5% premarket after the drugmaker posted 2Q sales ahead of expectations on the strength of its obesity drugs and raised FY’26 revenue full-year forecast above expectations. Foundayo revs (weight loss pill) launched in June beat expectations.

☀️ Pre-Market Earnings Recap:

$Eli Lilly(LLY.US) Q2 EARNINGS DOUBLE BEAT + RAISE 🔥